[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628489":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Genotype-guided Dosing Group","EXPERIMENTAL","All participants will receive 6-MP maintenance therapy with dosage adjustments based on their NUDT15 and TPMT genotype status.",[13],"Drug: NUDT15\u002FTPMT genotype-guided 6-MP dosing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","NUDT15\u002FTPMT genotype-guided 6-MP dosing","Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:\n\nNormal metabolizers: 100% standard dose (50-75 mg\u002Fm\\^2\u002Fd). Intermediate metabolizers: 30-80% of the recommended dose. Poor metabolizers: 10-30% of the recommended dose. Subsequent dosage adjustments are made based on toxicity monitoring and therapeutic drug monitoring (TDM) of 6-TGN and 6-MMP levels.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Tian Xia, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"tian xia, MD","CONTACT","+86 15267035696","xiatiansky2013@163.com",[32],{"facility":5,"status":20,"city":33,"state":34,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hangzhou","Zhejiang","China","CN",{"type":38,"coordinates":39},"Point",[40,41],120.16142,30.29365,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":46,"phoneExt":20,"email":30},"Tian Xia, PhD","86-15267035696",{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"xiatian","Attending Physician",[51],{"name":52,"class":6},"Zhejiang University","100628489","nudt15tpmt-multi-gene-guided-6-mp-dosing-in-childhood-all-maintenance-therapy-100628489",false,"NCT07462299","NUDT15\u002FTPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy","A Prospective Study of NUDT15\u002FTPMT Multi-gene Combined Guidance on 6-MP Dosage During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\nDiagnosed with ALL and scheduled for maintenance therapy. Plan to receive oral 6-MP. NUDT15 and TPMT genotyping results available. Baseline liver and kidney function within acceptable limits (ALT\u002FAST ≤ 2.5xULN, etc.).\n\nSigned informed consent. -\n\nExclusion Criteria:\n\nDown syndrome. Relapsed\u002Frefractory disease before maintenance. Prior hematopoietic stem cell transplantation. Severe organ dysfunction or uncontrolled infection.\n\n\\-","ALL","1 Year","18 Years",{"count":64,"type":65},110,"ESTIMATED","INTERVENTIONAL",[68],"NA","This is a prospective, single-center clinical study to evaluate the safety and efficacy of a personalized 6-mercaptopurine (6-MP) dosing strategy guided by NUDT15 and TPMT genotypes in children with Acute Lymphoblastic Leukemia (ALL) during maintenance therapy. The study compares this gene-guided strategy with historical controls to assess if it reduces the incidence of Grade ≥3 neutropenia and infection events.",[71],"Childhood Acute Lymphoblastic Leukemia",[73,74,75,76,77],"NUDT15","TPMT","6-MP","Pharmacogenetics","Maintenance Therapy","NOT_YET_RECRUITING","2026-03-05",{"date":81,"type":82},"2026-03-10","ACTUAL",{"date":84,"type":65},"2026-02-20",{"date":86,"type":65},"2028-12-31",{"name":5,"class":6},1]